Patent · US Expired

Pyrrolotriazine kinase inhibitors

US7173031B2 · kind B2 · utility

16Cited by
29References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 24, 2005
Grant dateFeb 6, 2007
Priority date
Expiry dateJun 24, 2025

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D495/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

In general, the instant invention comprises compounds of Formulas I and IIincluding pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.